title: Development of the placental villous tree and its consequences for fetal growth.
abstract: Co-ordinated development of the fetal villous tree of the placenta is necessary for continued fetal growth and well-being. Before fetal viability, blood vessel development within the developing immature intermediate villi (IIV) is characterized by branching angiogenesis, such that the placenta expands to produce 10-16 generations of stem villi. Once fetal viability is attained, a developmental switch occurs to form large numbers of gas-exchanging terminal villi (TV) by non-branching angiogenesis in mature intermediate villi (MIV). Several growth factors, including vascular endothelial growth factor (VEGF), placenta growth factor (PlGF), angiopoietins, and angiostatins are produced within the villi and act locally, via their receptors, to control angiogenesis. Their relative contributions to placental vascular development are not fully understood at the present time. Severe early-onset intrauterine growth restriction (IUGR) is characterized by absent/reversed end-diastolic flow velocity (ARED) in the umbilical arteries, leading to fetal hypoxia, acidosis and a substantial rise in perinatal mortality and morbidity. The placentas from such cases show a deficit in peripheral villous development, which may be perpetuated by the effects of oxygen (delivered by maternal blood into the intervillous space) upon VEGF-directed angiogenesis, the so-called 'placental hyperoxia' theory of villous maldevelopment. Trophoblast apoptosis is a significant feature of early-onset IUGR and may explain poor flow-independent transfer of nutrients to the fetus. Finally, since transgenic mouse studies highlight the importance of trophoblast-derived transcription factors for placental villous (labyrinth) development, it is possible that the villous trophoblast controls the orderly development of the underlying mesoderm and blood vessels into the fetal villi.
authors.affiliation: Department of Obstetrics & Gynecology, Maternal-Fetal Medicine Division, Mount Sinai Hospital, University of Toronto, 600 University Avenue, Ont., M5G 1X5, Toronto, Canada. jkingdom@mtsinai.on.ca
authors.forename: J
authors.initials: J
authors.lastname: Kingdom
authors.forename: B
authors.initials: B
authors.lastname: Huppertz
authors.forename: G
authors.initials: G
authors.lastname: Seaward
authors.forename: P
authors.initials: P
authors.lastname: Kaufmann
mesh_terms: D000818:Animals; D001158:Arteries; D002824:Chorionic Villi / Q000502:physiology*; D005260:Female; D005317:Fetal Growth Retardation / Q000209:etiology / Q000503:physiopathology*; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000150:complications; D000860:Hypoxia / Q000150:complications; D051379:Mice; D009389:Neovascularization, Pathologic; D010920:Placenta / Q000098:blood supply / Q000503:physiopathology*; D011247:Pregnancy
chemical_list: D006133:Growth Substances